## Andrew A Kanner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12170371/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Detection of gene mutations and gene–gene fusions in circulating cellâ€free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis. Molecular Oncology, 2022, 16, 2098-2114.	2.1	13
2	Height in adolescence as a risk factor for glioma subtypes: a nationwide retrospective cohort study of 2.2 million subjects. Neuro-Oncology, 2021, 23, 1383-1392.	0.6	5
3	Multicentric non-enhancing lesions in glioblastoma: A retrospective study. Journal of Clinical Neuroscience, 2021, 85, 20-26.	0.8	1
4	Height as a risk factor in meningioma: a study of 2 million Israeli adolescents. BMC Cancer, 2020, 20, 786.	1.1	7
5	TAMI-40. TUMOR MICROBIOME AND GLIOBLASTOMA (GBM). Neuro-Oncology, 2020, 22, ii221-ii222.	0.6	4
6	PATH-24. DETECTION OF POINT MUTATIONS AND GENE FUSIONS FROM CIRCULATING CELL-FREE DNA (CFDNA) OF GLIOBLASTOMA (GBM) PATIENTS. Neuro-Oncology, 2020, 22, ii169-ii169.	0.6	0
7	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. JAMA Oncology, 2018, 4, 495.	3.4	135
8	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. World Neurosurgery, 2018, 110, e727-e737.	0.7	14
9	Neurocognitive evaluation of brain metastases patients treated with post-resection stereotactic radiosurgery: a prospective single arm clinical trial. Journal of Neuro-Oncology, 2018, 140, 307-315.	1.4	6
10	Combined treatment approach to cerebral arteriovenous malformation in pediatric patients: stereotactic radiosurgery to partially Onyx-embolized AVM. Child's Nervous System, 2018, 34, 2269-2274.	0.6	13
11	Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature. Journal of Clinical Neuroscience, 2017, 37, 51-53.	0.8	23
12	Impact of Onyx Embolization on Radiosurgical Management of Cerebral Arteriovenous Malformations: Treatment and Outcome. World Neurosurgery, 2017, 108, 656-661.	0.7	9
13	Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2017, 135, 545-552.	1.4	48
14	Future Directions for Tumor Treating Fields. , 2016, , 117-126.		0
15	Supportive Care in Patients Using Tumor Treating Fields Therapy. , 2016, , 103-116.		1
16	Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. Journal of Neuro-Oncology, 2016, 126, 551-557.	1.4	24
17	Craniectomy Versus Craniotomy for Posterior Fossa Metastases: Complication Profile. World Neurosurgery, 2016, 89, 193-198.	0.7	18
18	Corrigendum to "Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100A™ System Versus Best Physician's Choice Chemotherapy'' [Seminars in Oncology, Vol No 5,Suppl 6, October 2014, pp S25-S34]. Seminars in Oncology, 2015, 42, e56-e66.	<b>@</b> ]\$	1

#	Article	IF	CITATIONS
19	SURG-26COMPLICATION PROFILE: COMPARING CRANIECTOMY AND CRANIOTOMY FOR POSTERIOR FOSSA METASTASES. Neuro-Oncology, 2015, 17, v220.1-v220.	0.6	Ο
20	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA - Journal of the American Medical Association, 2015, 314, 2535.	3.8	982
21	Patterns of Failure after Stereotactic Radiosurgery of the Resection Cavity FollowingÂSurgical Removal of Brain Metastases. World Neurosurgery, 2015, 84, 1825-1831.	0.7	20
22	Post Hoc Analyses of Intention-to-Treat Population in Phase III Comparison of NovoTTF-100Aâ,,¢ System Versus Best Physician's Choice Chemotherapy. Seminars in Oncology, 2014, 41, S25-S34.	0.8	80
23	Should the subventricular zone be part of the "rad―zone?. Journal of Neuro-Oncology, 2014, 118, 423-424.	1.4	3
24	RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results. Practical Radiation Oncology, 2014, 4, 76-81.	1.1	205
25	Synergy-S stereotactic radiosurgery for spinal tumors. Israel Medical Association Journal, 2013, 15, 678-81.	0.1	1
26	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. European Journal of Cancer, 2012, 48, 2192-2202.	1.3	661
27	Radiosurgical treatment planning of AVM following embolization with Onyx: possible dosage error in treatment planning can be averted. Journal of Neuro-Oncology, 2010, 98, 271-276.	1.4	51
28	Radiotherapy of nonfunctioning and gonadotroph adenomas. Pituitary, 2009, 12, 15-22.	1.6	19
29	Surgical Therapies in Brain Metastasis. Seminars in Oncology, 2007, 34, 197-205.	0.8	16
30	The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. Journal of Neurosurgery, 2006, 104, 542-550.	0.9	43
31	Posterior Fossa Metastases: Risk of Leptomeningeal Disease When Treated with Stereotactic Radiosurgery Compared to Surgery. Journal of Neuro-Oncology, 2004, 67, 115-121.	1.4	60
32	Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer, 2003, 98, 1465-1472.	2.0	29
33	Posterior Fossa Metastases: Aggressive Treatment Improves Survival. Stereotactic and Functional Neurosurgery, 2003, 81, 18-23.	0.8	32
34	Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience. Journal of Neurosurgery, 2002, 97, 1115-1124.	0.9	62